Post-treatment Novmalized Urodynamiz Findings as the Golden Standard of Objective Cure for Female Overactive Bladder Patients Receiving Antimuscarinic Drug

Not Applicable

• Conditions: Overactive Bladder Syndrome
• Interventions: Drug: Solifenacin

• Registration Number: NCT01627145
• Lead Sponsor: National Taiwan University Hospital

Brief Summary

Post-treatment Novmalized Urodynamiz Findings as the Golden Standard of Objective Cure for Female Overactive Bladder Patients Receiving Antimuscarinic Drug and Its Conelations With Voiding Diary, King's Health Quentionaire, Overactive Bladder Sympton Scores and Patient Perception of Bladder Condition.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2012-06-21
• Study First Submitted QC: 2012-06-22
• Study First Posted: 2012-06-25
• Study Start: 2012-08
• Status Verified: 2012-11
• Last Update Submitted: 2012-11-14
• Last Update Posted: 2012-11-15
• Primary Completion: 2015-01
• Study Completion: 2015-07

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: Female
• Target Recruitment: 300

Inclusion Criteria

• female patients within 18 years old to 99 years old with overactive bladder syndrome

Exclusion Criteria

• unwilling or unable to perform testing procedure

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
antimuscariniz drug	Solifenacin	-

Primary Outcome Measures

Name	Time	Method
The percentage of normalized urodynamic pattern after treatment	12 weeks

Secondary Outcome Measures

Name	Time	Method
The percentage of recurrence rates after treatment during follow-up and further to analyze the risk factors of recurrence	48 months

Trial Locations

Locations (1)

No 8, Chung-Shan South Road,; 🇨🇳 Taipei, Taiwan